10-QPeriod: Q2 FY2020

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2020

Filed July 31, 2020For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported a solid second quarter in 2020, demonstrating resilience despite the ongoing COVID-19 pandemic. Total revenue increased by 2.8% year-over-year to $637.6 million, driven primarily by strong performance in the Companion Animal Group (CAG) segment, which saw a significant recovery in diagnostic recurring revenues. The company's operational efficiency improved, with gross profit margin increasing by 180 basis points and operating income from operations rising by 17.6% to $193.2 million. Financially, IDEXX maintained a strong liquidity position, with cash and cash equivalents increasing to $105.3 million. The company also proactively managed its debt, enhancing financial flexibility with a $1 billion revolving credit facility and issuing $200 million in senior notes. While the Water segment experienced a revenue decline due to pandemic-related disruptions, the overall financial health and operational recovery of IDEXX highlight its ability to navigate challenging economic conditions and deliver value to its shareholders.

Financial Highlights

52 data points
Beta

Revenue

$637.59M

59.5% Gross Margin

Net Income

$149.00M

23.4% Net Margin

EPS (Diluted)

$1.72

Total Assets

$1.96B

Cash & Equivalents

$105.29M

Free Cash Flow

$183.59M

Financial Statements
Beta
Revenue$637.59M
Cost of Revenue$258.25M
Gross Profit$379.34M
R&D Expenses$31.64M
Operating Income$193.25M
Interest Expense$9.49M
Net Income$149.00M
EPS (Basic)$1.75
EPS (Diluted)$1.72
Shares Outstanding (Basic)85.13M
Shares Outstanding (Diluted)86.40M

Key Highlights

  • 1Total revenue for the second quarter of 2020 increased by 2.8% to $637.6 million compared to the prior year.
  • 2Companion Animal Group (CAG) segment revenue grew by 3.4% to $566.1 million, with recurring diagnostic revenue showing a strong recovery and growing 6.9%.
  • 3Gross profit margin improved by 180 basis points to 59.5%, indicating enhanced operational efficiency and favorable product mix.
  • 4Income from operations increased by a significant 17.6% to $193.2 million, reflecting effective cost management.
  • 5Cash and cash equivalents increased to $105.3 million as of June 30, 2020, up from $90.3 million at the end of 2019.
  • 6The company maintained a strong liquidity position with $877.0 million in remaining borrowing availability under its $1 billion revolving credit facility.
  • 7Revenue from the 'Other' segment, driven by the new OPTI COVID-19 PCR test, saw substantial growth of 127.8%.

Frequently Asked Questions

The COVID-19 pandemic had a mixed impact. While it initially pressured diagnostic testing volumes and led to deferred new instrument placements in the Companion Animal Group (CAG), there was a strong recovery starting in late April through June. The Water segment experienced a revenue decline due to disruptions in testing and reduced non-compliance testing. The 'Other' segment saw significant revenue growth driven by the new OPTI COVID-19 PCR test.

IDEXX demonstrated strong financial health and liquidity. Cash and cash equivalents increased to $105.3 million. The company has significant borrowing capacity with $877 million available under its $1 billion revolving credit facility and also issued $200 million in senior notes, enhancing its financial flexibility.

The Companion Animal Group (CAG) was the primary driver of growth, with recurring diagnostic revenues showing a robust recovery. The Livestock, Poultry and Dairy (LPD) segment saw a slight revenue increase excluding currency impacts. The Water segment experienced a decline in revenue. The 'Other' segment, boosted by the COVID-19 test, saw exceptional growth.

The improvement in gross profit margin was attributed to higher sales volumes, a favorable product mix (strong IDEXX VetLab consumables and lower instrument revenue), price increases, productivity gains, and cost controls in reference laboratories. The introduction of the OPTI COVID-19 PCR test also contributed positively.